Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa

Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review

“…A case report of a 30-year-old female patient with severe HS showed significant improvement after 13 months of subcutaneous ixekizumab therapy following failure of antibiotics, surgery, radiation, and other biologics such as ustekinumab, adalimumab, and infliximab [4]. Similarly, several other case reports corroborate improvement of HS with ixekizumab treatment as short as 4 weeks after treatment initiation [5][6][7]. Notably, none of these patients experienced adverse effects from ixekizumab therapy.…”

“…Notably, none of these patients experienced adverse effects from ixekizumab therapy. [4][5][6][7] Importantly, there are reports of paradoxical HS exacerbations in patients treated with Seborrheic dermatitis…”

Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants

“… Ref Name of Vaccines Type of Vaccines Vaccines Developer Clinical dose regimen Efficacy on original variants of SARS CoV2 Country (Voysey et al., 2021) (Knoll and Wonodi, 2021) [ 23 , 24 ] (University of Oxford/AstraZeneca) AZD1222 Viral vector (ChAdOx1-5) University of Oxford/AstraZeneca 2 Doses (4 weeks apart) Overall, 70.4% (95% CI 54.8–80.6) 2-standard dose: 62.1% (95% CI 41.0–75.7) Low dose + standard dose: 90.0% (95% CI 67.4–97.0) UK (Tehrani and Sajadi, 2021) [ 32 ] (Johnson and Johnson) Ad26.COV2. S Viral vector-based (Ad26) Johnson and Johnson (J&J) 1 Dose 66.9% (95% CI 59.0–73.4) ≥60 years old 76.3% (95% CI, 61.6–86.0) USA (Logunov et al., 2021) [ 41 ] Gamaleya (Sputnik V) Adeno based rAd26+rAd5 (Viral vector) (Genetically modified virus) Gamaleya Research Institute, Russia 2 Doses (3 weeks apart) 91.6% (95% CI 85.6–95.2) Russia [ 45 ] CanSino (Convidecia) recombinant adenovirus type-5 (Ad5) vector Beijing Institute of Biotech and CanSino Biological 1 Dose 65.7% (As per company own claim) Full data Unpublished China (Polack et al., 2020) [ 48 ] Pfizer (BNT162b2) mRNA Pfizer and BioNTech 2 Doses (3 weeks apart) 94.6% (95% CI 89.9–97.3) USA and Germany (Baden et al., 2021) [ 54 ] Moderna (mRNA-1273) …”

“… S. No (Genetic Variants of SARS CoV2) First Identified Spike protein substitutions (Mutations) (University of Oxford/AstraZeneca) AZD1222 (Johnson and Johnson) Ad26.COV2. S Pfizer (BNT162b2) Gamaleya (Sputnik V) Novavax NVX-CoV2373 Covaxin (Bharat Biotech) 1 Original Wuhan reference strain China, December 2019 References strain 55–81% (Voysey et al., 2021) [ 23 ] 66% (Tehrani and Sajadi, 2021) [ 32 ] 95% (Polack et al., 2020) [ 48 ] 91.6% (Logunov et al., 2021) [ 41 ] 89.7% (Heath et al., 2021) [ 60 ] 77.8% (Ella et al., 2021) [ 68 ] 2 B.1.1.7 (Detected in UK) 20I/501. Y. V1 (Alpha) United Kingdom 69del,70del,144del N501Y, A570D, D614G, S982A, D1118H, K1191 N, P681H, T716I 74.5% (Davies et al., 2021) [ 26 ] Unknown ∗93.7% effectiveness (Lopez Bernal et al., 2021) [ 30 ] Unknown 85.6% efficacy (Heath et al., 2021) [ 60 ] Unknown 3 B.1.351 (Detected in SA) 20H/501.V2 (Beta) South Africa D80A, D215G, 241del, 242del, 243del, N501Y, D614G, A701V, K417 N, E484K 10 (Madhi et al., 2021) % [ 28 ] 64–66% in USA (Shrestha, 2021) [ 33 ] ∗95% effective against severe disease and death [ 34 ] Virus-neutralizing activity with 3.1-fold (Gushchin et al., 2021) [ 42 ] 60.1% (Mahase, 2021b) [ 61 ] …”

“…In the final Phase III trial over 43,000 participants (16 years or older) were enrolled and underwent randomization into two separated groups assigned to receive either two doses of BNT162b2 vaccine (30 μg per dose) or placebo 21 days apart. There primary analysis from the phase III trial demonstrated a 94.6% efficacy (95% (CI) 89.9–97.3%) ( Table 1 ) in preventing against COVID 19, this conclusion was based on 170 cases of COVID 19 study, 8 cases were reported positive for COVID 19 after a week of the second dose in BNT162b2 group and 162 cases from among those receiving the placebo (NCT04368728) [ 48 ]. Data released by (PHE) found to prevent symptomatic cases of Alpha variant with 93.7% (95% CI, 91.6–95.3) ( Table 2 ) effectiveness within two weeks after the second dose and 88% (95% CI, 85.3–90.1) ( Table 2 ) effectiveness rate against the symptomatic COVID 19 diseases with Delta variant, two weeks after the second dose [ 30 ].…”